Top 10 best selling anticancer drugs in 2017: keytruda grows by more than 170%!

Source: medical economic news January 17, 2018 cancer drugs are the largest treatment field in the market According to the data of evaluatepharma, the global cancer drug market reached 93.7 billion US dollars in 2016 It is predicted that this figure will grow at a compound annual growth rate of 12.7% and double to US $192.2 billion by 2022 Meanwhile, the share of anticancer drugs in the global pharmaceutical market will also expand from 11.7% in 2016 to 17.5% in 2022 During this period, three products on the top 10 list of best-selling anticancer drugs are expected to be important drivers of market expansion in this treatment area: keytruda of Merck & Co, revimid of celgene, and opdivo of Bristol Myers Squibb In addition, the epacadostat which imfinzi and Incyte of AstraZeneca are still in phase III clinical practice will also be an important thrust The rise of these new stars will make up for the loss of revenue of Herceptin and rituxan in the top 10 list caused by the competition of bio similar drugs According to the sales data of the first three quarters of 2017 disclosed by relevant enterprises, Gen website lists the top 10 best-selling anticancer drugs Among them, Revlimid topped the list with a sales volume of US $5.999 billion; rituxan, Herceptin and Avastin, the three swordsmen of Roche's monoclonal antibody, ranked 2-4 respectively, but the growth was weak Rituxan and Herceptin increased by 2.5% and 2.1% respectively compared with the same period, and Avastin declined even more Among the drugs on the list, neulasta, neupogen and Velcade also showed negative growth Compared with the data of the same period in 2016, keytruda boasts a growth rate of 173.3% In addition, the growth rates of opdivo, imbruvica and ibrance are also very impressive Top 10 best selling anticancer drugs in the first three quarters of 2017 note: neulasta is a follow-up product of neupogen, which can reduce the number of Drug Administration